Alzheimer's disease (AD) induces a widespread patho-logical extracellular accumulation of beta-amyloid (Ab) peptides that affects cortical networks underpin- ning cognitive functions. This is related to abnormal functional and effective brain connectivity as revealed by graph markers of resting-state eyes-closed electro-encephalographic (EEG) rhythms. Here we revised EEG studies in mild cognitive impairment and AD subjects showing that these markers are promising network disease endpoints for basic research and AD drug discovery.
Resting state EEG rhythms as network disease markers for drug discovery in Alzheimer's disease / Babiloni, Claudio; Infarinato, F; Triggiani, Ai; Lizio, Roberta; Del Percio, C; Marzano, N; Richardson, J. C.. - In: DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES. - ISSN 1740-6773. - 10:(2013), pp. e85-e90.. [10.1016/j.ddstr.2014.02.003]
Resting state EEG rhythms as network disease markers for drug discovery in Alzheimer's disease.
BABILONI, CLAUDIO;LIZIO, ROBERTA;Del Percio C;
2013
Abstract
Alzheimer's disease (AD) induces a widespread patho-logical extracellular accumulation of beta-amyloid (Ab) peptides that affects cortical networks underpin- ning cognitive functions. This is related to abnormal functional and effective brain connectivity as revealed by graph markers of resting-state eyes-closed electro-encephalographic (EEG) rhythms. Here we revised EEG studies in mild cognitive impairment and AD subjects showing that these markers are promising network disease endpoints for basic research and AD drug discovery.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
